Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BAY 1817080 in Participants With Impaired Hepatic Function (Classified as Child-Pugh A, B or C) in Comparison to Matched Controls With Normal Hepatic Function

Next Previous
Trial Profile

An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BAY 1817080 in Participants With Impaired Hepatic Function (Classified as Child-Pugh A, B or C) in Comparison to Matched Controls With Normal Hepatic Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eliapixant (Primary) ; Midazolam
  • Indications Cough; Endometriosis; Overactive bladder
  • Focus Pharmacokinetics
  • Sponsors Bayer

Most Recent Events

  • 05 Jan 2022 Status changed from active, no longer recruiting to completed.
  • 07 Dec 2021 Planned End Date changed from 24 Nov 2021 to 10 Dec 2021.
  • 03 Nov 2021 Planned End Date changed from 21 Oct 2021 to 24 Nov 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top